文献速递临床试验与 GCP流行病学与生物统计

SuDDICU试验中选择性消化道去污染的过程评估:加拿大站点实施保真度分析

A process evaluation of a randomized clinical trial of selective decontamination of the digestive tract in ventilated adults admitted to intensive care: the SuDDICU PE study.
PubMed 文献 · Trials · 2026-08-14

SuDDICU试验在澳大利亚和加拿大26个集群纳入9289例机械通气成人,评估选择性消化道去污染(SDD)对院内死亡率无影响但减少新发血培养阳性。本过程评估在加拿大站点采用混合方法量化参与者覆盖与干预保真度,发现中等保真度并识别多个实施驱动因素。

要点

  • 干预阶段筛查合格但未纳入比例19.1%,对照阶段1.4%。
  • 19.1%参与者未在入组6小时内启动口服或胃内SDD,IV组分3.8%。
  • 机械通气日中口服和胃内SDD全剂量保真度分别为60.5%和57.5%。

核心结论

  • 加拿大站点SDD实施保真度为中等,保真度驱动因素涉及CFIR全部领域。

研究设计与样本

  • 多方法过程评估,含参与者覆盖与干预保真度定量数据、关键知情人访谈和非参与观察,分析基于CFIR框架。
  • SuDDICU试验在澳大利亚和加拿大26个集群招募9289例机械通气成人,本过程评估在加拿大站点进行。

主要发现

  • 干预阶段筛查的3020例中577例(19.1%)合格但未纳入,对照阶段3297例中47例(1.4%)。
  • 1432例参与者中274例(19.1%)未在入组6小时内启动口服或胃内SDD组分,54例(3.8%)未启动IV组分。
  • 排除入组和拔管日,中位通气天数为5天(IQR 2,11),口服SDD全剂量保真度占7438/12299(60.5%)通气日,胃内占7076/12299(57.5%)。
  • IV抗生素4天给药期间,4663/5160(90.4%)天数实现100%保真度。
  • 访谈30名临床/研究人员并观察40小时,保真度驱动包括对试验重要性理解不一、试验复杂性导致额外工作负担、对口服SDD和抗生素副作用的担忧、缺乏持续实施教育、非工作时间研究人员不足及COVID-19大流行背景。

临床怎么用

  • 复杂试验实施需关注药物制备与给药流程简化、持续教育及非工作时间人员配置以提升保真度。

局限性

  • 过程评估仅限加拿大站点,定性发现可能受COVID-19大流行背景影响。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The SuDDICU trial evaluated the effectiveness of selective digestive decontamination (SDD), a prophylactic antibiotic regimen comprising oral, gastric and intravenous (IV) components in ventilated adults admitted to intensive care. The trial recruited 9289 participants in 26 clusters across Australia and Canada. There was no difference in the primary outcome of in-hospital mortality, but a reduction in new positive blood cultures and antibiotic organisms. We conducted a concomitant process evaluation in Canadian sites. Our objectives were to quantify participant reach, intervention fidelity and understand drivers of implementation. METHODS: Multiple methods process evaluation comprising quantitative data on participant reach and intervention fidelity, and qualitative data using key informant interviews and non-participant observation. Analyses were informed by the Consolidated Framework for Implementation Research (CFIR). RESULTS: Of 6317 patients screened in Canadian clusters, 577/3020 (19.1%) screened during the intervention phase were eligible but not included; 47/3297 (1.4%) in the control phase. There were 274/1432 (19.1%) participants without oral or gastric SDD components commenced within 6 h of enrolment; 54/1432 (3.8%) for the IV component. Excluding enrolment and extubation days, the median (IQR) number of ventilator days was 5 (2, 11), with 7438/12,299 (60.5%) ventilator days with 100% SDD oral dose fidelity and 7076/12,299 (57.5%) ventilator days with 100% SDD gastric dose fidelity. Considering all 4 days of IV antibiotic administration, there were 4663/5160 (90.4%) days with 100% fidelity. We interviewed 30 clinical/research team members and conducted 40 h of non-participant observation. Considering CFIR domains, individual, intervention, implementation and contextual influences on fidelity included (1) variable understanding of trial importance/objectives; (2) trial complexity, specifically drug preparation and administration resulting in additional and unanticipated workload, exacerbated at some sites due to physical ICU layout and usual drug preparation/administration practices; (3) concerns about the SDD oral aspect and overall antibiotic side effects; (4) lack of sustained implementation education; (5) lack of research staff availability out-of-hours; and (6) the broader context of running a complex trial during the COVID-19 pandemic. CONCLUSIONS: We identified moderate fidelity within the Canadian sites participating in the SuDDICU trial, with important fidelity drivers identified across all CFIR domains. TRIAL REGISTRATION: SuDDICU Trial-ClinicalTrials.gov NCT02389036 (registered 03/17/2015); https://clinicaltrials.gov/ct2/show/NCT02389036 .

来源:Trials,查看原文。版权归原作者所有。

引用

  1. Dainty KN, Seaton MB, Amog K, et al. A process evaluation of a randomized clinical trial of selective decontamination of the digestive tract in ventilated adults admitted to intensive care: the SuDDICU PE study. Trials. 2026. PMID: 42642777. doi:10.1186/s13063-026-09935-6

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。